Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff:

Lori Fafard, RN, BSN, CNRN, MSCN, CCRP
Laura Graffitti, RN, BSN, CNRN, MSCN, CCRP
Kristen Capriola, RN, BSN, SC
Stephanie Galarza, SC
Erin Vacey, Clinical Assistant

MONTHLY UPDATE ON CLINICAL TRIALS aS of 9/1/14 

Study Name

Study Coordinator(s)

Phone Extension

Study Population

Enrolling Y/N

ASSESS (CFTY720D2312) Site # 5046 - -
RRMS; new start Gilenya Y
AUSPEX Site #342 Laura, Lori 2207, 2205
HD; Xenazine new starts & switches that are currently on Xenazine Y
Biogen 221AD301 (AXA23464)

Phase III Alzheimers Disease, randomized, double-blind, placebo-controlled, parallel group to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic AD
Y
Biogen 109MS413


Open label phase IV evaluate whether a medication event monitoring system (MEMS) can improve adherence to Tecfidera Treatment in MS patients
Y
Chugai nmo/nmosd - -
NMO: Multi-center, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in pt’s with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) y
CAMMS03409 site 1160 Lori
2205 RRMS: Campath
n
ENDORSE 109-MS-303 Laura
2207 RRMS: extension study BG12 (Tecfidera)
n
ESTEEM 109-MS-401 (ICF 7-17-14)
Laura
2207 RRMS; observation new start Tecfidera LT benefit; determine reasons for SAE’s, DMT’s routine prescription utilization & effectiveness
y
EXPAND (CBAF)
-
- SPMS – oral agent
y
AMS04 (sub study to Expand)
Lori
2205
Above participants: NIH sponsored for Biomarkers in serum and CSF- IRB approval 2-5-15 – ICF received
Y
MANAGE 109MS403
Laura
2207 RRMS observation new start Tecfidera
Y
Cidp (cfty72012201) lori 2205 CIDP subjects; 11-26-14 received major revision guidelines to eCRF re: completion of Liver Event eCRF pages.
y
MANAGE 109MS403 Laura 2207
RRMS observation new start Tecfidera Y
PREIMERE (ORACLE) Laura 2207
Observation Study F/U N
PRISMS (AVANIR) Lori 2205
Pseudobulbar Affective Disorder Y
REDEFINE (EMR 200136-573) - -
Rebidose vs. Rebiject II Y
RESOUND (EMR 200136-586) - - Tecfidera to Rebif Y
RESPOND (109MS404) Laura 2207
12 Month Observational Tecfidera Y
ROCHE WA21093 Laura 2207
RRMS N
ROCHE WA25046 Laura 2207
RRMS N
STRATIFY 101JC402 Erin et al 2246
Tysabri JCV N
STRIVE (101MS407) Lori 2205
New Start Tysabri JCV (-) <3yrs Diagnosis N
TOPAZ
Lori
2205
Extension to CAMMS03409 Study
Y
TRANSITION (CFTY720D2405) Laura 2207
Tysabri Gilenya N
TYGRIS Lori 2205
New start Tysabri observational N
WILKENS Lori, Laura, Erin 2205, 2207, 2246
Neurotrax validation study MS pt's 95 subjects (15 of 95 normal controls) Y

Locations this service is offered at:

Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014